Former Assistant U.S. Attorney Joins Phoenix Life Sciences International as Company's Vice President of Regulatory Affairs
February 05 2019 - 4:46AM
InvestorsHub NewsWire
DENVER, CO --
February 05, 2019 -- InvestorsHub NewsWire -- Phoenix Life Sciences
International Limited (OTC: PLSI) (“Phoenix Life”), an
international adaptive healthcare solutions company, today
announced that David Steinman has joined as the company’s Vice
President of Regulatory Affairs.
David Steinman
holds over two decades of experience, including serving as
Assistant United States Attorney where he served 5 years handling
narcotics-related matters. Following his time with the States
Attorney’s Office, he worked for Nestle USA, Sun Microsystems and
RE/MAX LLC before becoming General Counsel for Concord
Energy.
“As Phoenix Life expands its international
operations, we are proud to add David Steinman to our leadership
team,” said Phoenix Life Sciences International CEO Martin Tindall.
“As we move forward with our mission to re-introduce plant-based
pharmaceuticals to mainstream healthcare, Mr. Steinman’s role will
be to further enhance the transparency and speed with which we
navigate the evolving regulatory climates of countries around the
world.”
“As global legalization of medical marijuana
continues to spread, I stand behind Phoenix Life in providing
patients in need with natural pharmaceutical alternatives to
traditional treatments,” said David Steinman. “My background in
controlled substances, combined with my time serving large
corporations, has given me the experience needed to serve Phoenix
Life’s unique nuances as medical marijuana moves toward
legalization and social acceptance.”
To learn more about Phoenix Life Sciences
International, please visit phoenixlife.co.
About Phoenix Life Sciences International
Limited
Phoenix Life Sciences International Limited is an
adaptive healthcare solutions company. Our business is to advance
research and integrate programs and manufacturing of products that
target and treat diabetes, pain, cancer, and address psychological,
gastrointestinal, autoimmune, neurological and sleep disorders. We
strive to create partnerships and integrate these programs for
human health into communities worldwide as part of our Global
Health Initiative.
FORWARD-LOOKING
STATEMENTS
Information contained in this press release
regarding Phoenix Life Sciences International, Limited and its
subsidiaries, (the “Companies”) may constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements. The words “plan”, “forecast”,
“anticipates”, “estimate”, “project”, “intend”, “expect”, “should”,
“believe,” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve, and are subject to, known and unknown risks, uncertainties
and other factors which could cause the Company’s actual results,
performance (financial or operating) or achievements to differ from
the future results, performance (financial or operating) or
achievements expressed or implied by such forward-looking
statements. The risks, uncertainties and other factors are more
fully discussed in the Company’s filings with the U.S. Securities
and Exchange Commission. All forward-looking statements
attributable to the Companies herein are expressly qualified in
their entirety by the above-mentioned cautionary statement. The
Companies disclaim any obligation to update forward-looking
statements contained in this press release, except as may be
required by law.
FOOD AND DRUG ADMINISTRATION (FDA)
DISCLOSURE
These statements have not been evaluated by the FDA
and therefore the products sold by Phoenix Life Sciences
International are not available in the U.S.
LEGAL DISCLOSURE
Phoenix Life Sciences International does not sell or
distribute any products in the United States that are in violation
of the United States Controlled Substances Act (US.CSA). This
company does not grow, sell, and distribute cannabis-based products
in the United States and is solely involved with the legal
distribution of medical cannabis-based products within certain
international markets outside of the United States.
Investor Contact: Phone: 1.888.717.5655 or international +1.720.699.7222 E-mail:
investor.relations@phoenixlife.co Media Contact: Kathryn Reinhardt CMW Media Kathryn@cmwmedia.com 619-972-3089
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Phoenix Life Sciences (CE) (USOTC:PLSI)
Historical Stock Chart
From Apr 2023 to Apr 2024